Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case

Tomoyuki Ikeuchi1, Mitsuhiro Yamamoto1, Hirokazu Toge1

  • 1Department of Respiratory Medicine, National Hospital Organization (NHO) Yonago Medical Center, Yonago, JPN.

Cureus
|March 16, 2026
PubMed
Summary

Tarlatamab immunotherapy can cause pseudoprogression in small-cell lung cancer patients. Blood test changes like decreased lymphocytes and elevated interleukin-6 may help distinguish this from true tumor progression.

Related Concept Videos